KRAS and lung adenocarcinoma: Previous studies showed that the mutation of EGFR and LRP1B were mutually exclusive in primary lung adenocarcinoma (24), while no studies have reported the site-specific mutual exclusion between KRAS and LRP1B. Nevertheless, given the limited sample size in individual locations, future studies are warranted to validate our findings.